NCT05350072 - Two-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome | Biotech Hunter

Enrollment

276

Participants

Timeline

Start Date

July 28, 2022

Primary Completion Date

May 7, 2025

Study Completion Date

May 6, 2027

Conditions

Sjogren Syndrome

Interventions

BIOLOGICAL

VAY736

ianalumab s.c.

OTHER

Placebo

placebo s.c.

Trial Locations (78)

2000

Novartis Investigative Site, Stockerau

3000

Novartis Investigative Site, Leuven

6800

Novartis Investigative Site, Ankara

8036

Novartis Investigative Site, Graz

9001

Novartis Investigative Site, Quetzaltenango

10050

Novartis Investigative Site, Hohhot

11501

Winthrop University Hospital, Mineola

13353

Novartis Investigative Site, Berlin

13385

Novartis Investigative Site, Marseille

14033

Novartis Investigative Site, Caen

15006

Novartis Investigative Site, A Coruña

16635

Altoona Center for Clin Res, Duncansville

21034

Novartis Investigative Site, Dijon

21224

The John Hopkins Jerome L Greene Sjogren, Baltimore

28034

Novartis Investigative Site, Madrid

28401

Carolina Arthritis Associates, Wilmington

29203

Prisma Health, Columbia

33321

West Broward Rheumatology Associates Inc, Tamarac

39245

Novartis Investigative Site, Gommern

41380

Novartis Investigative Site, Kocaeli

42270

Novartis Investigative Site, Saint-Priest-en-Jarez

44650

Novartis Investigative Site, Guadalajara

45402

STAT Research Inc, Dayton

46202

Indiana Univ School of Dentistry, Indianapolis

48013

Novartis Investigative Site, Bilbao

59037

Novartis Investigative Site, Lille

61469

Novartis Investigative Site, Gwangju

67063

Novartis Investigative Site, Ludwigshafen

70809

Ochsner Health System, Baton Rouge

75010

Novartis Investigative Site, Paris

75013

Novartis Investigative Site, Paris

75231

Metroplex Clinical Research, Dallas

76034

Precision Comprehensive Research, Colleyville

77030

Baylor College Of Medicine, Houston

77494

Houston Rheumatology & Arthrit, Katy

79106

Novartis Investigative Site, Freiburg im Breisgau

91056

Novartis Investigative Site, Erlangen

91405

Medvin Clinical Research, Van Nuys

97080

Novartis Investigative Site, Würzburg

100050

Novartis Investigative Site, Beijing

110011

Novartis Investigative Site, Shenyang

276000

Novartis Investigative Site, Linyi

330006

Novartis Investigative Site, Nanchang

430030

Novartis Investigative Site, Wuhan

510630

Novartis Investigative Site, Guangzhou

518020

Novartis Investigative Site, Shenzhen

710063

Novartis Investigative Site, Shanxi

4710243

Novartis Investigative Site, Braga

7500571

Novartis Investigative Site, Santiago

7500710

Novartis Investigative Site, Santiago

29055 450

Novartis Investigative Site, Vitória

36010 570

Novartis Investigative Site, Juiz de Fora

14048-900

Novartis Investigative Site, Ribeirão Preto

01409-902

Novartis Investigative Site, São Paulo

014010

Novartis Investigative Site, Baotou

030000

Novartis Investigative Site, Taiyuan

638 00

Novartis Investigative Site, Brno

148 00

Novartis Investigative Site, Prague

686 01

Novartis Investigative Site, Uherské Hradiště

01009

Novartis Investigative Site, Guatemala City

01010

Novartis Investigative Site, Guatemala City

01011

Novartis Investigative Site, Guatemala City

08406

Novartis Investigative Site, Vilnius

06700

Novartis Investigative Site, Mexico City

52-210

Novartis Investigative Site, Wroclaw

85 168

Novartis Investigative Site, Bydgoszcz

30-002

Novartis Investigative Site, Krakow

20-954

Novartis Investigative Site, Lublin

6301-858

Novartis Investigative Site, Guarda

1050-034

Novartis Investigative Site, Lisbon

1349-019

Novartis Investigative Site, Lisbon

1649-035

Novartis Investigative Site, Lisbon

S308433

Novartis Investigative Site, Singapore

06591

Novartis Investigative Site, Seoul

08208

Novartis Investigative Site, Sabadell

08916

Novartis Investigative Site, Badalona

06230

Novartis Investigative Site, Ankara

06500

Novartis Investigative Site, Ankara